Capital Fund Management (CFM)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.46M | Sell |
77,374
-159,068
| -67% | -$9.13M | 0.02% | 984 |
|
|
2026
Q1 | $14.3M | Sell |
236,442
-844,824
| -78% | -$49.2M | 0.06% | 421 |
|
|
2025
Q4 | $58.3M | Sell |
1,081,266
-27,191
| -2% | -$1.31M | 0.16% | 138 |
|
|
2025
Q3 | $50M | Buy |
1,108,457
+804,283
| +264% | +$37.6M | 0.13% | 192 |
|
|
2025
Q2 | $14.1M | Buy |
+304,174
| New | +$14.9M | 0.04% | 589 |
|
|
2024
Q4 | – | Sell |
-1,018,327
| Closed | -$56.9M | – | 2032 |
|
|
2024
Q3 | $52.7M | Sell |
1,018,327
-665,997
| -40% | -$31.2M | 0.14% | 192 |
|
|
2024
Q2 | $69.9M | Buy |
+1,684,324
| New | +$75.4M | 0.21% | 126 |
|
|
2023
Q1 | – | Sell |
-182,848
| Closed | -$12.9M | – | 1558 |
|
|
2022
Q4 | $13.2M | Sell |
182,848
-81,265
| -31% | -$6.13M | 0.09% | 317 |
|
|
2022
Q3 | $18.8M | Buy |
264,113
+209,468
| +383% | +$15.2M | 0.15% | 177 |
|
|
2022
Q2 | $4.21M | Sell |
54,645
-41,875
| -43% | -$3.19M | 0.04% | 562 |
|
|
2022
Q1 | $7.05M | Buy |
96,520
+67,070
| +228% | +$4.5M | 0.06% | 455 |
|
|
2021
Q4 | $1.84M | Sell |
29,450
-182,622
| -86% | -$10.7M | 0.01% | 1066 |
|
|
2021
Q3 | $12.5M | Buy |
212,072
+176,746
| +500% | +$11.6M | 0.09% | 301 |
|
|
2021
Q2 | $2.36M | Sell |
35,326
-49,488
| -58% | -$3.23M | 0.02% | 867 |
|
|
2021
Q1 | $5.35M | Buy |
84,814
+39,179
| +86% | +$2.44M | 0.06% | 400 |
|
|
2020
Q4 | $2.83M | Buy |
45,635
+33,711
| +283% | +$2.07M | 0.03% | 665 |
|
|
2020
Q3 | $719K | Sell |
11,924
-1,426
| -11% | -$85.8K | 0.01% | 960 |
|
|
2020
Q2 | $785K | Sell |
13,350
-503,628
| -97% | -$30.1M | 0.01% | 770 |
|
|
2020
Q1 | $28.8M | Buy |
516,978
+140,509
| +37% | +$8.59M | 0.45% | 35 |
|
|
2019
Q4 | $24.2M | Buy |
376,469
+326,171
| +648% | +$18.7M | 0.19% | 133 |
|
|
2019
Q3 | $2.55M | Buy |
+50,298
| New | +$2.36M | 0.02% | 716 |
|
|
2019
Q2 | – | Sell |
-580,563
| Closed | -$27M | – | 1607 |
|
|
2019
Q1 | $27.7M | Buy |
580,563
+551,200
| +1,877% | +$27.5M | 0.25% | 109 |
|
|
2018
Q4 | $1.53M | Sell |
29,363
-1,518,882
| -98% | -$81.6M | 0.01% | 949 |
|
|
2018
Q3 | $96.1M | Sell |
1,548,245
-237,700
| -13% | -$14.1M | 0.52% | 18 |
|
|
2018
Q2 | $98.8M | Buy |
1,785,945
+1,483,000
| +490% | +$80.1M | 0.52% | 13 |
|
|
2018
Q1 | $19.2M | Buy |
302,945
+115,965
| +62% | +$7.46M | 0.12% | 251 |
|
|
2017
Q4 | $11.5M | Buy |
+186,980
| New | +$11.7M | 0.06% | 368 |
|
|
2017
Q3 | – | Sell |
-352,724
| Closed | -$20.6M | – | 1526 |
|
|
2017
Q2 | $19.7M | Buy |
+352,724
| New | +$19.2M | 0.16% | 174 |
|
|
2017
Q1 | – | Sell |
-1,147,619
| Closed | -$62.9M | – | 1473 |
|
|
2016
Q4 | $67.1M | Sell |
1,147,619
-545,407
| -32% | -$29.8M | 0.58% | 21 |
|
|
2016
Q3 | $91.3M | Buy |
+1,693,026
| New | +$109M | 0.84% | 5 |
|
|
2016
Q2 | – | Sell |
-147,305
| Closed | -$10.4M | – | 1534 |
|
|
2016
Q1 | $9.41M | Buy |
+147,305
| New | +$9.29M | 0.09% | 262 |
|
|
2015
Q4 | – | Sell |
-166,811
| Closed | -$11M | – | 1545 |
|
|
2015
Q3 | $9.88M | Buy |
+166,811
| New | +$10.6M | 0.11% | 240 |
|
|
2014
Q4 | – | Sell |
-233,895
| Closed | -$13.2M | – | 1581 |
|
|
2014
Q3 | $12M | Sell |
233,895
-786,352
| -77% | -$39.3M | 0.13% | 186 |
|
|
2014
Q2 | $49.5M | Buy |
1,020,247
+713,293
| +232% | +$35.2M | 0.52% | 16 |
|
|
2014
Q1 | $15.9M | Buy |
+306,954
| New | +$16.3M | 0.2% | 112 |
|
Other funds holding BMY
Capital Fund Management (CFM)'s BMY Position: Q2 2026 in Review
Capital Fund Management (CFM) reduced its Bristol-Myers Squibb (BMY) stake by 67% in Q2 2026, selling an estimated $9.13M and leaving 77,374 shares worth $4.46M. The position accounts for 0.02% of the portfolio, ranked #984.
Capital Fund Management (CFM) first reported a position in BMY in Q1 2014 and has held it in 35 quarters since. The position peaked at $98.8M in Q2 2018. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Capital Fund Management (CFM) held 77,374 shares of Bristol-Myers Squibb worth $4.46M as of Q2 2026.
- Capital Fund Management (CFM) sold 159,068 Bristol-Myers Squibb shares in Q2 2026, an estimated $9.13M.
- Bristol-Myers Squibb made up 0.02% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #984 holding.
- Capital Fund Management (CFM) first reported a position in Bristol-Myers Squibb in Q1 2014 and has held it in 35 quarters since.
- Capital Fund Management (CFM)'s Bristol-Myers Squibb position peaked at $98.8M in Q2 2018.
- 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.